Predicting the death of patients with anti-melanoma differentiation–associated protein-5-positive dermatomyositis-associated interstitial lung disease: A systematic review and meta-analysis
Modern Rheumatology · 2024
DOI: 10.1093/mr/road042 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Baolu Yang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chaoyang Hospital, Capital Medical Univer…. Hauptthemen laut MEDLINE: Dermatomyositis, Lung Diseases, Interstitial. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
To investigate the risk factors for death in anti-melanoma differentiation–associated protein-5-positive dermatomyositis-associated interstitial lung disease (ILD).
Methods
Studies were identified by searching PubMed, Embase, Web of Science, and Cochrane Library. We calculated pooled risk ratios (RRs) or standardized mean differences (SMDs) and 95% confidence intervals (CIs) using random-effects models.
Results
Twenty studies were selected. Factors that may increase death risk included older age (SMD: 0.62, 95% CI: 0.42–0.81), elevated Krebs von den Lungen-6 (SMD: 0.66, 95% CI: 0.47–0.86), lactate dehydrogenase (SMD: 0.87, 95% CI: 0.72–1.02), C-reactive protein (SMD: 0.62, 95% CI: 0.44–0.80), ferritin (SMD: 0.93, 95% CI: 0.71–1.15), creatine kinase (SMD: 0.28, 95% CI: 0.13–0.44), neutrophil (SMD: 0.34, 95% CI: 0.04–0.64), neutrophil-to-lymphocyte ratio (SMD: 0.52, 95% CI: 0.24–0.79), aspartate aminotransferase (SMD: 0.70, 95% CI: 0.45–0.94), shorter disease duration (SMD: −0.44, 95% CI: −0.67 to −0.21), rapidly progressive ILD (RR: 4.08, 95% CI: 3.01–5.54), fever (RR: 1.98, 95% CI: 1.46–2.69), dyspnoea (RR: 1.63, 95% CI: 1.32–2.02), and anti-Ro52 antibody positive (RR: 1.28, 95% CI: 1.11–1.49). Female (RR: 0.86, 95% CI: 0.78–0.94), increased albumin (SMD: −1.20, 95% CI: −1.76 to −0.64), lymphocyte (SMD: −0.49, 95% CI: −0.67 to −0.30), and arthralgia (RR: 0.53, 95% CI: 0.37–0.78) were protective factors.
Conclusion
Older age, shorter disease duration, rapidly progressive ILD, fever, dyspnoea, anti-Ro52 antibody positive, and some inflammatory markers were risk factors for death in patients with anti-melanoma differentiation–associated protein-5-positive dermatomyositis-associated ILD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
- Department of Rheumatology and Clinical Immunology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Zhaohui Tong
Zitieren
APA
Yang, B., Liu, S., Qian, Z., & Tong, Z. (2024). Predicting the death of patients with anti-melanoma differentiation–associated protein-5-positive dermatomyositis-associated interstitial lung disease: A systematic review and meta-analysis. Modern Rheumatology. https://doi.org/10.1093/mr/road042
Vancouver
Yang B, Liu S, Qian Z, Tong Z. Predicting the death of patients with anti-melanoma differentiation–associated protein-5-positive dermatomyositis-associated interstitial lung disease: A systematic review and meta-analysis. Modern Rheumatology. 2024. doi:10.1093/mr/road042
BibTeX
@article{Yang2024,
author = {Yang, Baolu and Liu, Suying and Qian, Zhenbei and Tong, Zhaohui},
title = {Predicting the death of patients with anti-melanoma differentiation–associated protein-5-positive dermatomyositis-associated interstitial lung disease: A systematic review and meta-analysis},
journal = {Modern Rheumatology},
year = {2024},
doi = {10.1093/mr/road042}
}
EUVIMED